Home / Deep Research / Atelosteogenesis Type I

Atelosteogenesis Type I

**References:**

2026-03-03
OpenAI MONDO:0007167 Model: o3-deep-research-2025-06-26 69 citations

Overview: Atelosteogenesis type I (AOI) is a rare, perinatally lethal skeletal dysplasia characterized by incomplete bone formation (the term “atelosteogenesis” literally means “imperfect osteogenesis”) and severe disproportionate short stature (pmc.ncbi.nlm.nih.gov) (medlineplus.gov). It belongs to a spectrum of filamin B (FLNB)–related osteochondrodysplasias that also includes atelosteogenesis type III, Larsen syndrome, and boomerang dysplasia (pubmed.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). AOI is caused by heterozygous gain-of-function mutations in the FLNB gene, which encodes the cytoskeletal protein filamin B (pubmed.ncbi.nlm.nih.gov) (medlineplus.gov). These mutations disrupt normal skeletal development and result in a distinctive set of bone abnormalities. Only a few dozen cases of AOI have been reported worldwide (medlineplus.gov), underscoring its extreme rarity.

Pathophysiology: Filamin B is an actin-binding protein that stabilizes the cytoskeleton and plays a crucial role in endochondral ossification – the process by which cartilage is converted to bone during fetal development (medlineplus.gov). It is highly expressed in chondrocytes (cartilage-forming cells) and is essential for their proliferation, differentiation, and the formation of a normal growth plate (medlineplus.gov). In AOI, mutant FLNB proteins have an abnormal (gain-of-function) activity that perturbs cytoskeletal and signaling functions in developing cartilage (medlineplus.gov). The abnormal filamin B appears to acquire a new deleterious function that interferes with chondrocyte maturation and ossification, leading to delayed/incomplete mineralization of cartilage models and profound skeletal dysplasia (medlineplus.gov) (pmc.ncbi.nlm.nih.gov). Proposed mechanisms include marked delays in long bone ossification, reduced bone mineral density, and disorganized chondrocyte proliferation and apoptosis, as well as impaired cell motility in the growth plate (pmc.ncbi.nlm.nih.gov). On a molecular level, different FLNB mutations may perturb cell signaling in variable ways; for example, one recent cell-based study showed distinct FLNB variants differentially affect pathways like AKT and TGF-β/Smad in cartilage cells, which contributes to the heterogeneous skeletal outcomes (pmc.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). The end result of FLNB gain-of-function mutations is a severe failure of normal bone formation, especially in the spine and long bones, which explains the hallmark features of AOI (short, under-ossified bones with multiple deformities).

Genetics and Inheritance: FLNB is the major gene implicated in Atelosteogenesis I. AOI arises from dominant missense or small in-frame deletions in one copy of the FLNB gene, typically clustered in the filamin B actin-binding domain or nearby regions (pubmed.ncbi.nlm.nih.gov). These mutations act in a dominant gain-of-function manner rather than causing haploinsufficiency (pmc.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). Atelosteogenesis type III is allelic to type I – it is caused by other missense mutations in FLNB and considered a slightly less severe phenotype on the same spectrum (pmc.ncbi.nlm.nih.gov). In contrast, atelosteogenesis type II is a genetically distinct disorder caused by biallelic loss-of-function mutations in the sulfate transporter gene SLC26A2 (formerly DTDST) (pmc.ncbi.nlm.nih.gov). AOII is inherited in an autosomal recessive pattern, whereas AOI is autosomal dominant (pubmed.ncbi.nlm.nih.gov). Because AOI is usually lethal in the perinatal period, most cases are sporadic due to new (de novo) mutations arising in the germline; indeed, the vast majority of FLNB mutations causing lethal AOI are not inherited from an affected parent (www.ncbi.nlm.nih.gov). Rarely, somatic mosaicism in a parent can lead to transmission of AOI – there are reports of a mildly affected mosaic parent (with subtle skeletal anomalies) having an offspring with full-blown lethal AOI (pmc.ncbi.nlm.nih.gov). In one 2023 case, for example, an asymmetrically affected father was found to be mosaic (~20% of cells) for an FLNB missense mutation and passed it to his newborn, who had classic lethal AOI (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This highlights that while AOI follows dominant inheritance, de novo mutations and mosaicism are the predominant real-world scenarios for this disorder.

Hallmark Skeletal Phenotypes: AOI has a recognizable constellation of skeletal abnormalities evident on prenatal ultrasound or at birth. Key features include:

  • Severe disproportionate short-limbed dwarfism: infants have markedly shortened arms and legs (rhizomelic shortening) with overall small stature (www.ncbi.nlm.nih.gov). Long bones (humeri and femora) are hypoplastic, often tapered or bowed, reflecting undermineralization. The term “disharmonious skeletal maturation” has been used to describe the uneven development of the skeleton in AOI (pubmed.ncbi.nlm.nih.gov).
  • Large joint dislocations and foot deformities: congenital dislocations of the hips, knees, and elbows are typically present, due to malformation of joint structures (www.ncbi.nlm.nih.gov). Affected newborns often have clubfeet (inward- and upward-turning feet) at birth (medlineplus.gov). These joint instabilities and contractures are similar to those seen in the milder FLNB-related Larsen syndrome, but in AOI they are more severe and universal.
  • Thoracic and spinal abnormalities: The rib cage is small and underdeveloped, leading to a narrow thorax (thoracic hypoplasia) and under-inflated lungs (medlineplus.gov). This causes respiratory insufficiency, the primary reason why AOI is typically lethal shortly after birth (medlineplus.gov). The vertebrae are flattened (platyspondyly) and may be malformed, contributing to a short trunk (www.ncbi.nlm.nih.gov). The pelvis is hypoplastic as well, with small iliac wings and poor ossification of pelvic bones (www.ncbi.nlm.nih.gov).
  • Limb bone malformations: Many long bones are incomplete or missing. Radiographs show absent or extremely short fibulae, and the radius can be absent or shortened with resultant bowing of the ulna; the femur and humerus are shortened and may be “distally tapered” (pointed) at the ends (www.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Ossification is incomplete in many skeletal elements – for example, the metacarpal bones and the proximal/middle phalanges of the fingers often remain unossified or only partially ossified at birth (www.ncbi.nlm.nih.gov). This lack of ossification in the hands and feet, along with the long bone changes, is a hallmark diagnostic clue for AOI on prenatal imaging or X-rays (pmc.ncbi.nlm.nih.gov).
  • Craniofacial features: Babies with AOI often have distinctive facial dysmorphism. Common findings include a prominent forehead (frontal bossing), wide-set, bulging eyes (ocular hypertelorism with proptosis), a depressed nasal bridge with upturned nose, and micrognathia (small jaw) (medlineplus.gov) (www.ncbi.nlm.nih.gov). Despite the large appearing skull (often termed macrocranium or macrobrachycephaly), many cranial bones may have poor ossification. A cleft palate is occasionally present (medlineplus.gov). These craniofacial signs, while not life-threatening, can aid in recognizing the syndrome.
  • “Flipper-like” extremities in extreme cases: In the most severe end of the AOI spectrum (overlapping with boomerang dysplasia), infants can exhibit polysyndactyly with complete syndactyly of all digits, giving the limbs a paddle-like appearance (www.ncbi.nlm.nih.gov). In such cases, all fingers and toes are fused and there may be duplicate distal bones (described as “distal octadactyly” in hands) with absent or rudimentary thumbs (www.ncbi.nlm.nih.gov). This dramatic malformation reflects an even more profound disruption of skeletal patterning. While not present in every AOI case, this “flipper limb” presentation is considered part of the AOI spectrum and is pathognomonic when observed (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov).

Diagnosis and Current Research: Atelosteogenesis I can often be suspected prenatally by ultrasound findings of severe skeletal abnormalities (short limbs, small chest, joint dislocations). Genetic testing is then used to confirm the diagnosis. Modern Next-Generation Sequencing approaches – multi-gene panels or whole-exome sequencing (WES) – have greatly improved the ability to identify the causative mutation in cases of lethal skeletal dysplasia like AOI (pmc.ncbi.nlm.nih.gov). For example, exome sequencing in a 2014 case pinpointed a de novo FLNB missense mutation in an infant with AOI, demonstrating the efficacy of WES in reaching a definitive molecular diagnosis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Likewise, a recent report highlighted that recognizing subtle signs in a mosaic parent and testing for an FLNB variant enabled prenatal diagnosis of AOI in the fetus (pmc.ncbi.nlm.nih.gov). These diagnostic advances are critical for genetic counseling and early intervention, even though no curative treatment exists for AOI.

On the research front, ongoing studies are probing the mechanistic basis of FLNB mutations. The Genetics of AOI has been refined by gene discovery – FLNB’s role was first identified in the mid-2000s (pubmed.ncbi.nlm.nih.gov) and GeneReviews (updated 2025) now consolidates FLNB-related disorders as a spectrum (www.ncbi.nlm.nih.gov). Recent functional studies (2022–2023) are examining how different FLNB mutant proteins impact cell behavior. For instance, Wu et al. (2022) demonstrated that two distinct FLNB missense mutations had cell-dependent effects on chondrocyte signaling and gene expression, suggesting that FLNB variants can differentially disrupt pathways like PI3K–AKT and TGF-β/Smad, leading to variability in skeletal phenotypes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This line of research is helping to explain the range from milder Larsen syndrome to lethal AOI within the FLNB spectrum, and may eventually identify targets to modulate the disease process.

Conclusion: Atelosteogenesis type I is a genetically defined osteochondrodysplasia with a well-characterized mutation in a cytoskeletal protein (filamin B) as its cause. It exhibits an autosomal dominant inheritance pattern, though typically through de novo mutations. Mechanistically, a gain-of-function in filamin B disrupts the formation and ossification of cartilage, which manifests as profound skeletal abnormalities – from short, under-ossified long bones and dislocated joints to characteristic craniofacial features. The disorder’s hallmark skeletal phenotypes (severe short-limb dwarfism, joint dislocations, thoracic hypoplasia, and incomplete ossification of bones) correlate with the underlying molecular pathology in growth plate cartilage (medlineplus.gov) (www.ncbi.nlm.nih.gov). Ongoing research and advanced genomic diagnostics continue to refine our understanding of AOI, but it remains a lethal condition with no definitive treatment, emphasizing the importance of prenatal diagnosis and family planning in its management (medlineplus.gov). As our insight into filamin B’s role in skeletal development deepens, it provides a mechanistic framework not only for AOI but also for related skeletal dysplasias caused by FLNB, guiding both clinical recognition and future therapeutic ideas (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

References:

  1. Robertson SP & Meira J. FLNB-Related Disorders. GeneReviews. Last updated Sep 11, 2025 (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov).
  2. Farrington-Rock C et al. “Mutations in two regions of FLNB result in atelosteogenesis I and III.” Hum Mutat. 2006 Jul;27(7):705-10 (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).
  3. MedlinePlus Genetics. Atelosteogenesis Type 1. Reviewed Oct 2015 (updated) (medlineplus.gov) (medlineplus.gov).
  4. Jeon GW et al. “Identification of a de novo heterozygous missense FLNB mutation in lethal atelosteogenesis I by exome sequencing.” Ann Lab Med. 2014;34(2):134-138 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
  5. Wu H et al. “Cell-dependent pathogenic roles of filamin B in different skeletal malformations.” Biomed Res Int. 2022;2022:8956636 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
  6. Meira JGC et al. “Diagnosis of Atelosteogenesis I suggested by fetal ultrasonography and mosaic paternal phenotype.” Clinics (São Paulo). 2023;78:e4605 (PMC10316906) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).